TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2654467
Drug: Obsidan (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obsidan (0.1 mg/kg intravenously, then orally for 2-3 days every 3-4 hours, followed by 60-120 mg per 24 hours)
Study: 24381911
Drug: Submucosal tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal tramadol (2 mg/kg)
Study: 24381911
Drug: Isotonic solution
Normalized name: Isotonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic solution (control)
Study: 19388886
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (basic analgesic regimen of paracetamol and diclofenac)
Study: 14993578
Drug: Metadate CD
Normalized name: Metadate CD
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metadate CD (MCD) 20 mg, 40 mg, 60 mg
Study: 14993578
Drug: Metadate CD
Normalized name: Metadate CD
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metadate CD (MCD) 40 mg, 60 mg
Study: 14993578
Drug: Concerta (CON)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concerta (CON) 18 mg, 36 mg, 54 mg
Study: 9222707
Drug: Sucralfate suspension
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate suspension (2 x 2 g/day)
Study: 9222707
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional medicine (Control)
Study: 7897780
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of a nasal decongestant
Study: 3310717
Drug: Mixed grass
Normalized name: ALLERGENIC EXTRACT MIXED GRASSES INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed grass pollen allergens from rye grass, timothy grass, cultivated rye and velvet grass (administered daily for 1 year).
Study: 3310717
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered daily for 1 year).
Study: 3310717
Drug: Mixed grass
Normalized name: ALLERGENIC EXTRACT MIXED GRASSES INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed grass pollen allergens (administered daily for 1 year).
Study: 31529220
Drug: Indigo naturalis
Normalized name: indigo
DrugBank: Indigo (DB16862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indigo naturalis (0.5-2.0 g daily)
Study: 27787540
Drug: Oral voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral voriconazole (loading dose of 400 mg twice daily for 24 hours, followed by 200 mg twice daily for 20 days)
Study: 22023889
Drug: Pharmacist-physician collaboration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-physician collaboration intervention involving interviews and pharmaceutical care for a year.
Study: 22023889
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of adverse drug reactions and drug interactions.
Study: 22023889
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of drug interactions.
Study: 18752586
Drug: Titrated low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Titrated low-dose misoprostol
Study: 18752586
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction method (vaginal dinoprostone followed by intravenous oxytocin or intravenous oxytocin alone)
Study: 15497668
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg (Sinopryl)
Study: 15497668
Drug: Lisinopril/hydrochlorothiazide 20
Normalized name: lisinopril/hydrochlorothiazide 20 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril/hydrochlorothiazide 20 mg/12.5 mg (Sinoretik)
Study: 11738168
Drug: Single fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single fraction external beam radiation therapy (8 Gy)
Study: 8179082
Drug: Cefoxitin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (1 g intravenous every 8 hours starting at induction, three times)
Study: 31642930
Drug: Signs changed
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Signs changed weekly
Study: 31642930
Drug: Signs changed
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Signs changed monthly
Study: 30420367
Drug: Patellar mobilization
Normalized name: Oxtellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patellar mobilization therapy (PMT)
Study: 27509602
Drug: Meloxicam, 7.5
Normalized name: Meloxicam, 7.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam, 7.5 mg, once a day for 6 weeks.
Study: 17321111
Drug: Risperidone 4
Normalized name: risperidone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 4 mg/day for 6 weeks
Study: 11372795
Drug: 17 g
Normalized name: lancets 17 gauge MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 g of PEG daily for 4 days
Study: 11372795
Drug: PEG treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG treatment
Study: 16306137
Drug: PEG therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG therapy
Study: 11372795
Drug: PEG laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG laxative
Study: 31066646
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose regimen containing voclosporin, MMF and steroid therapy
Study: 31066646
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment with high dose MMF and steroids
Study: 16517764
Drug: G-CSF therapy
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF therapy (subcutaneous injections of 15 microg/kg per day for 5 days)
Study: 27819485
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Ω3 + PEP)
Study: 27819485
Drug: Omega-3 (Ω3)
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 (Ω3) monotherapy
Study: 27454370
Drug: Family systems
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family systems therapy
Study: 25060157
Drug: Yoghurt enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoghurt enriched with 2 g of plant stanol ester (PS group)
Study: 18990996
Drug: Immediate nonocclusal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate nonocclusal loading of dental implants
Study: 18990996
Drug: Early nonocclusal
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early nonocclusal loading of dental implants (6 weeks)
Study: 7104143
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg pindolol three times daily for 2 days
Study: 7104143
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg propranolol three times daily for 2 days
Study: 26853339
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus Radiation Therapy (RT) at a recommended phase 2 dose of 750 mg/m(2)/wk during the last 4 weeks of RT
Study: 26853339
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus Radiation Therapy (RT)
Study: 24408514
Drug: Topical Cyperus
Normalized name: Cyperus rotundus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cyperus rotundus oil
Study: 23022970
Drug: Colchicine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1.0 mg twice daily for the first day followed by 0.5 mg twice daily for 1 month in patients ≥70 kg; halved doses for patients <70 kg or intolerant)
Study: 10193294
Drug: Milrinone 50
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone 50 micrograms kg‐1 administered at the end of bypass
Study: 17569583
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate (SP) loading (1g of tribasic dodecahydrate sodium phosphate, four times daily for 6 days)
Study: 16958396
Drug: Protocol of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol of 150 ml of 300 mg I/ml
Study: 16958396
Drug: Protocol of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol of 100 ml of 300 mg I/ml
Study: 16958396
Drug: Protocol of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol of 100 ml of 350 mg I/ml
Study: 11129986
Drug: Neoadjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant tamoxifen (20 mg/day for 3 weeks)
Study: 9065902
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist treatment (triptorelin) for 6 months
Study: 1640278
Drug: Heparin (1/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (1/2 unit per milliliter of continuous intravenous infusate or intermittent heparin flush)
Study: 29798783
Drug: Matched warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched warfarin group
Study: 12866653
Drug: Lactate-buffered CVVH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate-buffered CVVH (treatment A)
Study: 12866653
Drug: Bicarbonate-buffered CVVH
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate-buffered CVVH (treatment B)
Study: 26862930
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with esomeprazole (20 mg), amoxicillin (1000 mg), and clarithromycin (500 mg) twice daily for 7 days
Study: 26862930
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with 5 days of esomeprazole (20 mg) and amoxicillin (1000 mg) twice daily, followed by 5 days of esomeprazole (20 mg), clarithromycin (500 mg) and metronidazole (400 mg) twice daily
Study: 26862930
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy with esomeprazole (20 mg), amoxicillin (1000 mg), clarithromycin (500 mg) and metronidazole (400 mg) twice daily for 7 days
Study: 18251659
Drug: Standard-of-care antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care antimicrobial therapy after surgical incision and drainage
Study: 16482080
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (1 g per day for 7 days)
Study: 11038990
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment applied to points: Touwei (ST 8), Xuanlu (GB 5), Fengchi (GB 20), Dazhui (GV 14), Lieque (LU 7), treated with the reducing method.
Study: 11038990
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug therapy (CDTG)
Study: 1577051
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose omeprazole (20 mg)
Study: 1577051
Drug: Short-term omeprazole
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term omeprazole treatment (20 mg/day for 8 days)
Study: 24627569
Drug: Atenolol treatment
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol treatment for 9 weeks
Study: 20823377
Drug: Theobromine-enriched cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theobromine-enriched cocoa (979 mg of theobromine)
Study: 20823377
Drug: Natural dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural dose theobromine cocoa (106 mg of theobromine)
Study: 11522234
Drug: CD56(+) cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD56(+) cell expandability after CT2 and G-CSF application
Study: 9590461
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg compressed tablet (CT)
Study: 9590461
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg sustained release (SR) tablet
Study: 3197978
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet with one dose of 90 g corn oil after the last meal (120 g fat/day)
Study: 3197978
Drug: Basal low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal low fat diet containing 30 g of fat per day
Study: 3197978
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet with doses of 30 g corn oil taken with each of the three meals (120 g fat/day)
Study: 30642738
Drug: Oral citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral citrulline supplementation (0.18 g/kg/day)
Study: 22525372
Drug: Houttuyninum (5.52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Houttuyninum (5.52 μg/ml IC50)
Study: 22525372
Drug: Houttuyninum (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Houttuyninum (in vivo administration)
Study: 22525372
Drug: Houttuyninum (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Houttuyninum (40 μg/ml)
Study: 19460169
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy directed to the talocrural joint
Study: 17529847
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg/d orally)
Study: 7624915
Drug: N‐SIM (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐SIM (300 mg single dose)
Study: 2190516
Drug: Erythromycin, 500
Normalized name: Erythromycin, 500 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin, 500 mg, four times daily for 3 weeks
Study: 38695
Drug: Pancuronium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.01 mg/kg
Study: 38695
Drug: Pancuronium 0.010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.010 to 0.020 mg/kg
Study: 25926146
Drug: Annual initial
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual initial in-hospital treatment cost for all AUGIB cases in the UK
Study: 21407248
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements (ONS) for 3 months and dietary counselling at discharge
Study: 17353582
Drug: Neptune Krill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neptune Krill Oil (NKO) 300 mg daily
Study: 11951578
Drug: Neuramide (N)
Normalized name: lauramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuramide (N) administered intramuscularly twice daily for 28 days
Study: 3377230
Drug: Maximal warming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal warming (warm room, humidified respiratory gases, and warm intravenous fluids)
Study: 31167512
Drug: Bergamot polyphenol
Normalized name: BERGAMOT
DrugBank: Bergamot oil (DB14335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bergamot polyphenol extract complex (BPE‐C) 650 mg daily
Study: 31167512
Drug: Bergamot polyphenol
Normalized name: BERGAMOT
DrugBank: Bergamot oil (DB14335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bergamot polyphenol extract complex (BPE‐C) 1300 mg daily
Study: 27846629
Drug: Drug-Eluting Balloon
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Balloon (DEB) after Cutting Balloon (CB) dilation
Study: 27846629
Drug: Drug-Eluting Stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Stent (DES) implantation alone
Study: 25791668
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (IT) - medical therapy plus psychotherapy (8 group and 2 individual sessions)
Study: 25791668
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (CT) - medical therapy alone
Study: 25791668
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (IT) - medical therapy plus psychotherapy
Study: 23571784
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch 6% (2 × 250 ml for 3 days postoperatively)
Study: 23571784
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution 0.9% (control group)
Study: 23571784
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch 6% and Saline solution 0.9%
Study: 21963127
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment (15, 30 or 60μg/kg daily)
Study: 19819787
Drug: Metoprolol 50
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50 mg daily
Study: 7719087
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (laparoscopy + TCM including low dose Methotrexate, modified Huo‐Luo‐Xiao‐Ling Dan, Ding‐Tong paste, Zi‐Gong pill)
Study: 31056272
Drug: SFC method
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC method applied to clinical samples after single intravenous (100 mg), single oral (100 mg), and repeated oral administration (400 mg)
Study: 16762702
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg preoperatively, 200 mg postoperatively)
Study: 15328782
Drug: Caffeine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (400 mg at 21:30, followed by 100 mg at 03:00 and 05:00)
Study: 10718163
Drug: Lamotrigine 125
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine 125 mg
Study: 10718163
Drug: Lamotrigine 250
Normalized name: lamotrigine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 250 mg
Study: 8883530
Drug: Iodixanol at
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol at 320 mg I/kg
Study: 1547766
Drug: Intrarectal diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal diazepam (DZP) 20 mg
Study: 1547766
Drug: Intrarectal diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal diazepam (DZP) 30 mg
Study: 2863922
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.5 mg fluphenazine and 10 mg nortriptyline (Motival)
Study: 2863922
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg fluphenazine
Study: 2863922
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nortriptyline
Study: 31593070
Drug: Nasal High
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal High Flow (NHF) therapy
Study: 23631607
Drug: Acarbose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (50 mg three times a day)
Study: 21839402
Drug: Ustekinumab (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (45 mg at Weeks 0 and 4)
Study: 16737665
Drug: Mistletoe lectin
Normalized name: MISTLETOE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe lectin (ML) derived from IQ
Study: 16737665
Drug: IQ depleted
Normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IQ depleted of ML
Study: 11680559
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus group drug counseling
Study: 11680559
Drug: Supportive-expressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive therapy plus group drug counseling
Study: 11680559
Drug: Individual drug
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual drug counseling plus group drug counseling
Study: 9770877
Drug: Coccinia indica,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coccinia indica, 500 mg/kg body weight, administered orally for six weeks
Study: 7819650
Drug: Lactobacillus preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus preparation
Study: 18849052
Drug: 12% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% sucrose solution (for children aged 6 to 48 months)
Study: 18849052
Drug: Lidocaine-prilocaine cream
Normalized name: lidocaine / prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine cream (for children aged 6 to 48 months)
Study: 15131545
Drug: Atorvastatin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin alone (to reduce LDL cholesterol to < or =80 mg/dL)
Study: 15131545
Drug: Atorvastatin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin plus antioxidant vitamins C and E (to reduce LDL cholesterol to < or =80 mg/dL)
Study: 15131545
Drug: Control (diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (diet and low-dose lovastatin to reduce LDL cholesterol to < or =130 mg/dL)
Study: 9040271
Drug: Combined physical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined physical therapy (twice a week for 60 minutes with a therapist, daily unsupervised exercise for 15 minutes)
Study: 9040271
Drug: Combined physical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined physical therapy
Study: 3116238
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I received a nutrient solution providing 10 grams of nitrogen as Perifusin and 1400 calories as dextrose and Intralipid with an osmolality of 490 mosmol/kg
Study: 30907987
Drug: Levothyroxine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (50 μg once daily)
Study: 28077730
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of measles vaccine (MV) at 18 weeks and 9 months
Study: 28077730
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of measles vaccine (MV) at age 9 months